Lemuteporfin injectable for benign prostatic hyperplasia marketing plan for QLT Inc.

This paper is a marketing plan for QLT Inc. for its third-generation photodynamic therapy drug, Lemuteporfin. The paper focuses specifically on marketing Lemuteporfin as a new, non-thermal minimally invasive therapy for benign prostatic hyperplasia. The paper provides an insight into the external environment, or the competitive marketplace, and establishes the rationale for entering this marketplace. With this rationale, the internal environment, or the opportunity for Lemuteporfin within QLT, is analyzed and the strategic opportunities and challenges are introduced, along with a tactical plan to address the implementation of the strategies for Lemuteporfin related to penetrating and growing the minimally invasive therapy market in benign prostatic hyperplasia.